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Background: Locoregional tumor failure (LRF) after definitive chemoradiation for patients with stage III NSCLC
remains unacceptably high. This analysis sought to further define where LRF occurs relative to radiation dose
received and pre-treatment PET scan-defined maximum standard uptake value (SUVmax).
Methods: This was a retrospective study analyzing patients with stage III NSCLC treated with definitive radiation
between 2006 and 2011. LRF was defined as failure within the ipsilateral lung, hilum or mediastinum. The CT
simulation scan with the radiation dose distribution was registered to the CT or PET/CT documenting LRF. The
region of LRF was contoured, and the dose to 95% of the volume (D95) of LRF was extracted. The pre-treatment
SUVmax was also extracted for the anatomic region of LRF.
Results: Sixty-one patients were identified. Median follow-up time was 19.1 months (range 2.37-76.33). Seventy four
percent of patients were treated with 3-D conformal technique (3DCRT), 15% were treated with Intensity Modulated
Radiotherapy (IMRT), and 11% were treated with a combination of 3DCRT and IMRT. Median prescribed radiation
dose for all patients was 66 Gy (39.6-74). Concurrent chemotherapy was delivered in 90% of patients. Twenty-two
patients (36%) developed a LRF, with a total of 39 anatomic regions of LRF identified. Median time to LRF was
11.4 months (3.5-44.6). Failures were distributed as follows: 36% were in-field failures, 27% were out-of-field failures,
18% were in-field and out-of-field failures, and 18% were in-field and marginal (recurrences within the field edge)
failures. There were no isolated marginal failures. Of the patients that developed a LRF, 73% developed a LRF with
an in-field component. Sixty-two percent of LRFs were nodal. The median pre-treatment SUVmax for the anatomic
region of LRF for patients with an in-field failure was 13. The median D95 of in-field LRF was 63 Gy.
Conclusions: LRF after definitive chemoradiation are comprised primarily of in-field failures, though out-of field
failures are not insignificant. Marginal failures are rare, indicating field margins are appropriate. Although radiation
dose escalation to standard radiation fields has not yielded success, using PET parameters to define high-risk regions
remains worthy of further investigation.
Keywords: Lung cancer, Locally advanced, Locoregional failure, PET/CT, Radiation, Chemotherapy* Correspondence: kristin.higgins@emory.edu
Department of Radiation Oncology, Emory University School of Medicine
and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
© 2014 Rajpara et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Rajpara et al. Radiation Oncology 2014, 9:187 Page 2 of 7
http://www.ro-journal.com/content/9/1/187Background
Lung cancer continues to be the leading cause of cancer
death in the United States [1]. In 2013, an estimated
228,000 new cases of lung cancer were diagnosed and
160,000 lung cancer-related deaths were estimated to
have occurred [1]. Non-small cell lung cancer (NSCLC)
accounts for 80% of all lung cancers, and approximately
30-40% of patients with NSCLC present with unresect-
able, locally advanced disease. Concurrent chemoradiation
was established as the standard of care for patients with
inoperable non-small cell lung cancer (NSCLC) by several
randomized trials performed in the 1990s that demon-
strated an overall survival benefit with the delivery of con-
current as compared to sequential chemoradiation [2-4].
Despite the survival benefit gained from concurrent
chemoradiation therapy, clinical outcomes, particularly
locoregional control, remain suboptimal. Previous stud-
ies have demonstrated local control rates of 50-70%,
but some have reported locoregional control rates as
low as 15% [2,3,5,6]. Achieving local control of disease
in NSCLC is important, as a recent meta-analysis dem-
onstrated local control significantly improves overall
survival results [5].
The use of positron emission tomography/computed
tomography (PET/CT) with 2-[18 F] fluoro-2-deoxy-D-
glucose (FDG) for staging patients with NSCLC has in-
creased over the past two decades and is now considered
standard of care in the diagnostic workup in patients
with newly diagnosed NSCLC. PET/CT has been shown
to have better sensitivity in detecting metastatic disease
and to significantly reduce the size of radiation treatment
volumes [7-9]. Another potential advantage of PET/CT
with FDG is the ability to quantitatively analyze results
by using the standardized uptake value (SUV). The SUV
of the primary tumor has been shown to correlate with
prognosis in NSCLC and may be a marker of disease
activity [10,11]. The predictive value of PET/CT is still
undefined, however PET/CT presents an opportunity to
develop imaging biomarkers to predict locoregional fail-
ure (LRF) and thus refine delivery of radiotherapy in pa-
tients with unresectable, non-metastatic NSCLC.
The present study analyzed LRF relative to radiation
treatment fields and radiation dose received, in an effort
to understand the adequacy of planning treatment volumes
and to define anatomic regions most at risk for LRF.
Additionally, the pretreatment SUVmax of regions of LRF
were analyzed to determine if these regions had a higher
SUVmax relative to anatomic regions without LRF.
Methods
An Emory University Institutional Review Board ap-
proved study was performed on newly diagnosed, stage
III NSCLC patients undergoing curative intent radio-
therapy between 2006 and 2011. ICD-9 codes were usedto identify patients with lung cancer treated with radio-
therapy between 2006 and 2011. Inclusion criteria in-
cluded patients with AJCC (7th edition) Stage IIIA and
Stage IIIB, newly diagnosed, histologically confirmed
NSCLC treated with curative intent radiotherapy. Patients
included in this study were treated at Emory University
Hospital or Emory University Hospital Midtown. Patients
with disease other than stage III were excluded, as were
stage III patients treated with surgery and postoperative
radiation or patients treated with preoperative chemoradi-
ation. Patients without pre-treatment PET/CT imaging or
post-treatment (PET/CT or chest CT) imaging at Emory
University were excluded from this study.
Clinical characteristics of patients were extracted from
the electronic medical chart, including age, sex, race,
histology, T stage, N stage, and administration of chemo-
therapy. Details of radiation treatment, including dose,
treatment technique, and use of daily on-board imaging
were obtained through the radiation oncology electronic
chart as well as radiation oncology treatment planning
software.
Defining and analyzing locoregional tumor failures
Locoregional tumor failure was defined as recurrent or
persistent disease involving the ipsilateral lung, hilum, or
mediastinum. Radiology reports and radiology examina-
tions including CT and/or PET/CT were reviewed to de-
termine LRF. Biopsy was not required for confirmation of
LRF if serial imaging confirmed persistent or recurrent
disease. Supraclavicular recurrences and contralateral lung
recurrences were scored as distant failures. Locoregional
failures were included as either a first failure event or co-
incident with distant failure.
For patients who developed a LRF, the CT simulation
scan with radiation dose distribution was registered to
either the post-treatment CT or PET/CT that docu-
mented a LRF. A commercial deformable image regis-
tration and dose mapping software (VelocityAI, Velocity
Medical Solutions, Atlanta, GA), was used to register
the two image studies and extract both dose and SUVmax
from the region of interest. The deformable registration
algorithm uses free-form deformations based on cubic
spline interpolation between sparse, uniformly distributed
control points as its transformation model and has been
previously described in detail [12-14]. The anatomic re-
gion of LRF within the lung, mediastinum, or hilum was
contoured, using characteristics including soft-tissue full-
ness, contrast enhancement, asymmetry and FDG avidity
to distinguish tumor from normal, adjacent tissue. Recur-
rences involving lung parenchyma were contoured on a
lung window and recurrences involving soft tissue were
contoured on a soft tissue window. A dose volume histo-
gram was created to determine the dose to 95% (D95) of
the volume of LRF. Locoregional failures were determined
Table 1 Patient and treatment characteristics
Characteristics Patients, n = 61
Median age (range) 65 (40–84)
Sex
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(greater than 2 cm outside the 95% isodose line), or mar-
ginal (within 2 cm of the 95% isodose line) based on the
relation of the LRF region to the anatomic region encom-
























3-D Conformal 45 (74%)
IMRT 9 (15%)Integrating Pre-treatment PET/CT
The pre-treatment PET/CT was used to determine the
pre-treatment SUVmax of the anatomic region of LRF.
SUVmax was defined as the maximum SUV to a voxel
location contained within the primary tumor and the in-
volved lymph nodes. The region of LRF was contoured,
using the methods described above, on the CT scan doc-
umenting LRF. Using the previously described deform-
able image registration software (VelocityAI), the post-
treatment CT scan was registered to the pre-treatment
PET/CT scan, and the pre-treatment SUVmax was ex-
tracted in the region of LRF. A single user (R.R) per-
formed all image registrations, contouring of LRF, and
SUVmax determination.
The SUVmax was quantitatively used to determine
FDG-PET activity. SUV was defined as normalizing the
tumor uptake of FDG to injected dose per body weight
of the patient. SUVmax was defined as the maximum
SUV value at a pixel in the volume of interest and was
calculated by the image registration software (VelocityAI)
from the absolute activity (Bq/mL) in each voxel.
Descriptive statistics were used to illustrate the patient
population. Student t- tests were used to compare median
pre-treatment SUVmax values for patients with LRF
versus those patients without LRF, and to compare pre-
treatment SUVmax values in anatomic regions of LRF
relative to pre-treatment SUVmax values in patients
without LRF.3-D Conformal & IMRT 7 (11%)
Radiation Dose, median (range) 66 Gy (39.6-74 Gy)
Treatment Planning Margins, median (range)
GTV to CTV expansion 0.5 cm (0–1 cm)
CTV to PTV expansion 1 cm (0.3-2.5 cm)
Use of daily On-board Imaging (OBI) 24 (39%)
Concurrent Chemotherapy 55 (90%)
*NSCLC NOS- non-small cell carcinoma not otherwise specified.Results
Patient characteristics
Sixty-one patients met inclusion criteria for this study.
Patient and treatment characteristics are summarized in
Table 1. The median age at diagnoses was 65 (range 40–84).
Median follow-up time was 19.1 months (range 2.4-
76.3 months). The majority of patients (64%) presented
with Stage IIIB disease. The most common histology
was adenocarcinoma, consisting of 49% of cases. Concur-
rent chemotherapy was administered in 90% of patients. A
platinum-based doublet regimen was administered to all
patients receiving concurrent chemotherapy. Carboplatin
was given with paclitaxel (42 patients, 76%), pemetrexed
(4 patients, 7%), and etoposide (1 patient, 2%). Cisplatin
was given with etoposide (6 patients, 11%), pemetrexed
(1 patient, 2%), and docetaxel (1 patient, 2%). Six patients
received radiotherapy alone. The median radiation dose
was 66 Gy (range 39.6-74 Gy). The median pretreatmentSUVmax of the primary tumor and involved lymph nodes
for the entire patient cohort was 15.2 (range 6.6-50.1).
Treatment characteristics
All patients underwent CT-based radiation planning. All
patients underwent a pretreatment PET/CT that was used
to define radiation treatment volumes. Seventy-four percent
of patients were treated with 3-D conformal radiotherapy
(3DCRT), 15% were treated with IMRT, and 11% were
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treated with 3DCRT, 35 (78%) patients were treated with
anterior-posterior (AP) and posterior-anterior (PA) fields
followed by off-cord oblique fields. Seven, 8, or 9-field
IMRT was used for the patients treated with IMRT tech-
nique. The median gross tumor volume (GTV) to clinical
target volume (CTV) margin used was 0.5 cm (range
0–1.0 cm). The median CTV to planning target volume
(PTV) margin used was 1 cm (range 0.3-2.5 cm). Elective
nodal radiation of non-metabolically active nodal stations
was generally not performed. Heterogeneity corrections
for treatment planning were used in 31% of patients. On-
board imaging, consisting of KV (kilovoltage) orthogonal
films, was used in 39% of patients.
Locoregional tumor failure analysis
Twenty-two patients developed a LRF. The median time
to a LRF was 11.4 months (range 3.5-44.6 months). The
median radiation dose for patients that developed a LRF
was 66 Gy (range 45–66.6 Gy). The median pre-treatment
SUVmax of the primary tumor and lymph nodes was 14.9
(range 7.9-50.1) in patients with LRF, but was not signifi-
cantly different compared with the median pre-treatment
SUVmax (15.8, range 6.6-38.6) of patients without LRFs.
Five patients developed isolated LRF whereas 17 patients
developed LRF and distant failure. Of the 22 patients who
developed a LRF, 8 patients developed isolated in-field fail-
ures, 6 patients developed isolated out-of-field failures, 4
patients developed in-field and out-of-field failures, and 4
patients developed in-field and marginal failures (Table 2,
Figures 1, 2 and 3). No patient developed a marginal fail-
ure alone. In total, 73% of patients with a LRF had an
in-field component of recurrence. Isolated out-of-field
failures occurred in 27% of patients that developed a
LRF. Of the out-field recurrences, three patients developed
out-of-field nodal recurrences, two patients developed out-
of-field lung recurrences, and one patient developed both
an elective nodal failure and out of field lung recurrence.
Thus, LRF in elective nodal regions occurred in 7% of the
entire patient cohort.
A total of 39 anatomic regions of failure were identi-
fied in the 22 patients that developed a LRF. Fifteen
(38%) failures occurred within the parenchyma of the
lung and 62% occurred in regional lymph nodes. A totalTable 2 Patient specific local regional failures in relation
to radiation treatment fields
Location of local regional failure n = 22 (36%)
In-Field 8 (36%)
In-field and Marginal 4 (18%)
Out-of-field 6 (27%)
In-field and Out-of-field 4 (18%)
Marginal (isolated) 0 (0%)of 22 (56%) anatomic regions of failures occurred in
field, 13 failures occurred out of field, and 4 failures oc-
curred in the field edge (Table 3). The median pre-
treatment SUVmax for anatomic regions with an in-field
failure was 13.4 (range 4.8-43) and was not statistically
different from the median SUVmax of patients without a
LRF (15.8, range 6.6-38.6). The median D95 to the ana-
tomic region that failed in-field was 63.4 Gy (range 21.3-
69.5 Gy). Of the 22 anatomic regions of in-field failure,
12 failures (55%) occurred in the treated mediastinum
and 10 failures occurred within the treated lung paren-
chyma. In the 8 patients with isolated in-field LRFs, a
total of 11 anatomic regions were identified; 6 failures
occurred within the treated mediastinum and 5 within
the treated lung parenchyma. In the 6 patients with iso-
lated out-of-field LRFs, a total of 8 anatomic regions
were identified; 5 within the untreated mediastinum, and
3 within the untreated lung parenchyma. Isolated out-of-
field LRFs accounted for 21% of all anatomic regions of
failure.
Discussion
Locoregional tumor failure after definitive chemoradiation
for Stage III NSCLC remains high despite contemporary
radiation techniques and the addition of concurrent
chemotherapy. A 36% crude LRF rate was found in this
study, which is comparable to previous reports [2,3,5].
Interestingly, in this study, despite the use of PET/CT-
based planning and a median radiation dose of 66 Gy,
LRF after definitive radiation is primarily an in-field event
(73%). The marginal failure rate in this study is low, in-
dicating that the GTV to CTV and CTV to PTV margin
expansions used in this study are likely appropriate to
account for microscopic extent of disease and treatment
setup error and tumor motion, respectively.
In-field LRF was not due to inadequate dose, as the
median D95 to the anatomic region of LRF was 63 Gy,
indicating the region of LRF did receive a tumoricidal
dose of radiation. This median dose to regions of LRF is
similar to that mandated to the PTV in clinical trials,
which typically require 95% of the PTV to receive 100%
of the prescription dose. Thus, these anatomic regions
where in-field LRF is occurring likely represent radioresis-
tant disease. Strategies to overcome radiation resistance
continue to evolve. The Radiation Therapy Oncology
Group (RTOG) is currently examining dose escalation
to persistently metabolically active disease defined by
in-treatment FDG PET (RTOG 11–06). Other strategies
under investigation include the addition of molecular
agents to standard chemoradiation that target radioresis-
tant pathways.
Curing patients with locally advanced NSCLC is not
possible without locoregional disease control. Improving
local control has been shown to impact overall survival
Figure 1 In-field recurrence. A.) PET/CT 1 year post-treatment demonstrating recurrence in the posterior right lung. B.) Region of PET recurrence
contoured and fused to original CT simulation scan. Dose wash on CT simulation reveals the recurrence to be an in-field recurrence with a D95% to
the volume of recurrence of 62 Gy.
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concurrent chemoradiation versus sequential chemother-
apy and radiation [5]. Phase I and II studies evaluating
radiation dose escalation to 74 Gy revealed promising re-
sults with significant improvements in progression free
survival and overall survival [15-18]. Because of these early
promising results, RTOG 06–17 studied the question of
dose escalation in a phase III setting. The final results re-
garding the question of dose were recently presented in
abstract form, which revealed a detriment to dose escal-
ation in terms of locoregional failure and overall survival
[19]. The LRF rate at 18 months was 35.3% for the 60 Gy
arm and 44% for the 74 Gy arm. Based on the results of
RTOG 06–17, radiation dose escalation at 2 Gy per frac-
tion does not appear to be the answer to improving local
control for patients with Stage III NSCLC, and other strat-
egies are needed to optimize locoregional control.
In this study, 55% of in-field LRFs occurred within the
involved mediastinum. Recently, investigators at University
of Kentucky reported outcomes of a pilot study evaluating
a stereotactic body radiation therapy (SBRT) boost to re-
sidual primary lung disease for stage IIA-IIIB NSCLC after
60 Gy of concurrent chemoradiation. Though medianFigure 2 Out-of-field recurrence. A.) CT scan 1 year post-treatment dem
B.) Region of recurrence contoured and fused to original CT simulation sca
recurrence with a D95% of 1 Gy.follow-up was quite short at 13 months, actuarial local
control was 83% [20]. While this approach may be prom-
ising, it does not address the mediastinum, which is the
more common site of in-field recurrence. At Emory, a
phase I dose escalation study to determine the maximum
tolerated dose of a SBRT boost to residual primary lung
and mediastinal disease after concurrent chemoradiation
to a dose of 44 Gy with standard fractionation is currently
ongoing.
The use of FDG PET/CT for patients with NSCLC has
dramatically increased over the past two decades. In-
creasing SUVmax of the primary tumor has been associ-
ated with a reduction in disease-free survival and overall
survival in patients with early stage NSCLC treated with
SBRT [21]. FDG PET will likely yield to the development
of imaging biomarkers that can aid in predicting LRF in
the locally advanced NSCLC population. Determining if
pre-treatment SUVmax or other pre-treatment FDG
PET parameters are associated with LRF after definitive
chemoradiation for Stage III NSCLC is intriguing as this
could lead to tailoring of radiation dose escalation to
areas thought to be at higher risk for failure. In this
study, the median pre-treatment SUVmax for anatomiconstrating a recurrence involving a right paratracheal lymph node.
n. Dose wash on CT simulation scan demonstrates an out-of-field
Figure 3 Marginal recurrence. A.) PET/CT 4 months post-treatment
demonstrating SUV uptake in a right paratracheal lymph node. B.) and
C.) Region of recurrence contoured and fused to original CT simulation
scan. Dose wash on CT simulation scan demonstrates a marginal
recurrence with a D95% of 50 Gy in a coronal view and axial
view, respectively.
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cally different from the SUVmax of patients who did not
develop a LRF. While pre-treatment SUVmax as a poten-
tial marker for regions at risk of LRF may not be useful,
other PET parameters are currently being explored, in-
cluding in-treatment FDG/PET CT in the ongoing RTOG
11–06 protocol.Table 3 All cumulative sites of local regional failure




This study demonstrates that in-field recurrence, par-
ticularly nodal recurrence, is the primary mode of LRF
after definitive radiotherapy for locally advanced NSCLC.
Marginal failures are rare and in-field recurrences are
receiving the intended radiation dose. Intrinsic radiore-
sistance is likely contributing to persistent LRF despite im-
provements in radiation techniques. Pretreatment SUVmax
was not associated with LRF in this study, but the use of
other PET parameters to determine high-risk regions for
LRF remains worthy of further investigation.
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